JP2022524391A5 - - Google Patents

Info

Publication number
JP2022524391A5
JP2022524391A5 JP2021553767A JP2021553767A JP2022524391A5 JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5 JP 2021553767 A JP2021553767 A JP 2021553767A JP 2021553767 A JP2021553767 A JP 2021553767A JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5
Authority
JP
Japan
Prior art keywords
cancer
oncolytic virus
synthetic oncolytic
synthetic
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021553767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524391A (ja
JP7561134B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013069 external-priority patent/WO2020185293A1/en
Publication of JP2022524391A publication Critical patent/JP2022524391A/ja
Publication of JP2022524391A5 publication Critical patent/JP2022524391A5/ja
Priority to JP2024163492A priority Critical patent/JP7904878B2/ja
Application granted granted Critical
Publication of JP7561134B2 publication Critical patent/JP7561134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021553767A 2019-03-08 2020-01-10 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用 Active JP7561134B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024163492A JP7904878B2 (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
US62/815,611 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024163492A Division JP7904878B2 (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用

Publications (3)

Publication Number Publication Date
JP2022524391A JP2022524391A (ja) 2022-05-02
JP2022524391A5 true JP2022524391A5 (cg-RX-API-DMAC7.html) 2023-01-23
JP7561134B2 JP7561134B2 (ja) 2024-10-03

Family

ID=69526302

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553767A Active JP7561134B2 (ja) 2019-03-08 2020-01-10 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用
JP2024163492A Active JP7904878B2 (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024163492A Active JP7904878B2 (ja) 2019-03-08 2024-09-20 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用

Country Status (19)

Country Link
US (3) US11717548B2 (cg-RX-API-DMAC7.html)
EP (2) EP4729621A3 (cg-RX-API-DMAC7.html)
JP (2) JP7561134B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250171410A (cg-RX-API-DMAC7.html)
CN (3) CN122146794A (cg-RX-API-DMAC7.html)
AU (1) AU2020233788A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017637A8 (cg-RX-API-DMAC7.html)
CA (1) CA3132714A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021013417A2 (cg-RX-API-DMAC7.html)
DK (1) DK3934673T3 (cg-RX-API-DMAC7.html)
ES (1) ES3066636T3 (cg-RX-API-DMAC7.html)
FI (1) FI3934673T3 (cg-RX-API-DMAC7.html)
IL (1) IL285963A (cg-RX-API-DMAC7.html)
MX (1) MX2021010808A (cg-RX-API-DMAC7.html)
MY (1) MY207334A (cg-RX-API-DMAC7.html)
PH (1) PH12021552145A1 (cg-RX-API-DMAC7.html)
PT (1) PT3934673T (cg-RX-API-DMAC7.html)
SG (1) SG11202109514VA (cg-RX-API-DMAC7.html)
WO (1) WO2020185293A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
DK3934673T3 (da) * 2019-03-08 2026-04-07 Massachusetts Inst Technology Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN116987736A (zh) * 2022-03-04 2023-11-03 上海行深生物科技有限公司 自复制rna分子和新冠病毒多价疫苗
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
AU2024208643A1 (en) * 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
JP2026513963A (ja) * 2023-04-07 2026-05-01 フラッグシップ ラブズ 114, インコーポレイテッド 治療用脂質ナノ粒子(lnp)の送達のための脂質および脂質様化合物
CN118147171B (zh) * 2024-03-08 2024-12-06 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列
KR20260046366A (ko) 2023-07-25 2026-04-07 스트랜드 세러퓨틱스 인코포레이티드 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도
CN122319231A (zh) * 2023-10-27 2026-06-30 上海元宋生物技术有限公司 溶瘤病毒及其用途
WO2026041140A1 (zh) * 2024-08-23 2026-02-26 康希诺(上海)生物研发有限公司 一种自复制rna分子及其制备方法和应用
CN119479778B (zh) * 2024-10-16 2025-04-25 北京悦康科创医药科技股份有限公司 一种lnp转染效率预测模型构建方法及装置
WO2026165118A1 (en) 2025-01-29 2026-08-06 Strand Therapeutics Inc. Polynucleotides comprising detargeting sensors and uses thereof
CN121081290B (zh) * 2025-11-12 2026-03-10 佑嘉(杭州)生物医药科技有限公司 一种毛囊靶向递送系统及生发防脱化妆品

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
FI4005592T3 (fi) * 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
EP2925352B1 (en) * 2012-12-03 2019-10-02 Ohio State Innovation Foundation Ehrlichial invasin for immunization, diagnosis, and cell delivery
ES2969956T3 (es) * 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
CN122564053A (zh) * 2014-10-31 2026-08-14 麻省理工学院 递送生物分子至免疫细胞
WO2016187531A1 (en) * 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
DK3934673T3 (da) 2019-03-08 2026-04-07 Massachusetts Inst Technology Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi
JP2023535225A (ja) * 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
US20240140960A1 (en) * 2021-02-12 2024-05-02 Ohio State Innovation Foundation Sugar derived lipid nanomaterials and uses thereof
JP2024527345A (ja) * 2021-07-09 2024-07-24 リプリケイト バイオサイエンス,インコーポレイティド 改変東部ウマ脳炎ウイルス、自己複製rna構築物、及びその使用
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法

Similar Documents

Publication Publication Date Title
FI3934673T3 (fi) Synteettinen onkolyyttinen lnp-replikoni-rna ja sen käyttöjä syövän immunoterapiaan
Yaremenko et al. Clinical advances of mRNA vaccines for cancer immunotherapy
Huang et al. A bimetallic nanoplatform for STING activation and CRISPR/Cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses
Li et al. mRNA vaccine in cancer therapy: Current advance and future outlook
Parato et al. Recent progress in the battle between oncolytic viruses and tumours
Nadeem et al. A Virus‐Spike Tumor‐Activatable Pyroptotic Agent
Liong et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery
Ladak et al. The current Landscape of mRNA vaccines against viruses and cancer–a mini review
Strods et al. Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications
Zhang et al. Self‐Oxygenated biomimetic nanozyme for tumor catalytic immunotherapy
Bahreyni et al. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy
JP2023535225A5 (cg-RX-API-DMAC7.html)
Rachamala Translational advances in lipid nanoparticle drug delivery systems for cancer therapy: current status and future horizons
Hromic-Jahjefendic et al. Viral vector-based melanoma gene therapy
Vasilevska et al. Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon
Newman et al. Infection: a cause of and cure for cancer
Anjum et al. Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach
Abdessalem et al. Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells
Ghazizadeh et al. Advances in cancer nanovaccines: a focus on colorectal cancer
Habibizadeh et al. Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: a review
Adesokan et al. SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments
Xing et al. Research progress of nanoparticles in diagnosis and treatment of hepatocellular carcinoma
Abdel-Rashid et al. Fabrication of gold nanoparticles in absence of surfactant as in vitro carrier of plasmid DNA
Ermi et al. Gene therapy strategies for hepatocellular carcinoma (HCC): current landscape and future directions
Joo et al. Emerging roles of using small extracellular vesicles as an anti-cancer drug